Jazz Pharmaceuticals Plc - Company Profile
Powered by 
All the data and insights you need on Jazz Pharmaceuticals Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Jazz Pharmaceuticals Plc Strategy Report
- Understand Jazz Pharmaceuticals Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Jazz Pharmaceuticals Plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Erwinaze (asparaginase erwinia chrysanthemi), Defitelio (defibrotide sodium), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
Fifth Fl, Waterloo Exchange, Waterloo Road, Dublin, 4
Website
www.jazzpharma.com
Telephone
353 1 6347800
No of Employees
2,800
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
JAZZ (NASD)
Revenue (2022)
$3.7B
18.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
32%
(2022 vs 2021)
Market Cap*
$7.6B
Net Profit Margin (2022)
XYZ
42.5%
(2022 vs 2021)
* As of and is in US$
Jazz Pharmaceuticals Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Xyrem |
| Xyrem (Sodium Oxybate) Oral Solution | Xywav |
| Xywav (Calcium, magnesium, potassium, and sodium oxybates) Oral solution | Kidrolase |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company and The University of Texas MD Anderson Cancer Center entered into a research agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers. |
| 2023 | Contracts/Agreements | In September, the company received approval for Enrylaze from The European Commission to treat acute lymphoblastic leukaemia and lymphoblastic lymphoma. |
| 2023 | Others | In April, the company partnered into Zymeworks for rapidly expanding oncology advances product portfolio. |
Competitor Comparison
| Key Parameters | Jazz Pharmaceuticals Plc | AstraZeneca Plc | Amgen Inc | Biogen Inc | Endo International Plc |
|---|---|---|---|---|---|
| Headquarters | Ireland | United Kingdom | United States of America | United States of America | Ireland |
| City | Dublin | Cambridge | Thousand Oaks | Cambridge | Dublin |
| State/Province | - | England | California | Massachusetts | - |
| No. of Employees | 2,800 | 83,500 | 25,200 | 8,725 | 2,861 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Bruce C. Cozadd | Chairman; Chief Executive Officer | Executive Board | 2012 | 59 |
| Renee Gala | President; Chief Operating Officer | Senior Management | 2023 | - |
| Neena M. Patil | Chief Legal Officer; Executive Vice President | Senior Management | 2019 | - |
| Heidi Manna | Senior Vice President; Chief Human Resources Officer | Senior Management | 2018 | - |
| Finbar Larkin, Ph.D. | Senior Vice President - Technical Operations | Senior Management | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward